|
Jul 30
|
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
|
|
Jul 30
|
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jun 27
|
Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?
|
|
Jun 24
|
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
|
|
Jun 24
|
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
|
|
Jun 21
|
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
|
|
Jun 17
|
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
|
|
May 23
|
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
|
|
May 23
|
It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope
|
|
May 16
|
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
|
|
May 11
|
Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
|
|
May 9
|
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
|
|
May 8
|
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
|
|
May 7
|
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 7
|
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 2
|
Why Earnings Season Could Be Great for Arvinas (ARVN)
|
|
May 2
|
Arvinas to Present at Upcoming Investor Conferences
|
|
May 1
|
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Apr 30
|
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
|
|
Apr 26
|
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|